Company / Accounts Receivable
Arbutus Biopharma Corp Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$1.4M
FY2025
5-year range
$899.0K / $2.4M
FY2021-FY2025
Trend
-39.9%
vs FY2024
Sector context
#103 of 113
Health Care
What the data says
Among 113 Health Care companies, Arbutus Biopharma Corp is in the bottom 9% for accounts receivable. Accounts Receivable has fluctuated over the past 10 years, ranging from $273,000 in FY2016 to $2M in FY2024.
Based on SEC 10-K filings.
$1M in FY2025 with a 5-year CAGR of +2.0%.
Declined from $2M to $1M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +2.3%
- 5-Year CAGR
- +2.0%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 113This company $1.4M Sector average $1.1B
▼
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.0%, indicating consistent growth.
- In FY2025, accounts receivable decreased 39.9% year-over-year.
- Ranks #103 out of 113 companies in the Health Care sector.
- Peak accounts receivable was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -11.01 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.4M | -39.9% |
| FY2024 | $2.4M | +35.6% |
| FY2023 | $1.8M | +31.4% |
| FY2022 | $1.4M | +50.4% |
| FY2021 | $899.0K | -31.5% |
| FY2020 | $1.3M | +9.0% |
| FY2019 | $1.2M | -15.9% |
| FY2018 | $1.4M | +256.0% |
| FY2017 | $402.0K | +47.3% |
| FY2016 | $273.0K | -72.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026